Edwards Lifesciences (EW) Stock Forecast & Price Target

$77.50 -0.51 (-0.65%)

Closing price 09/12/2025 03:59 PM Eastern

Extended Trading

$77.47 -0.03 (-0.03%)

As of 09/12/2025 07:31 PM Eastern

Compare

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy

Based on 24 Analyst Ratings

Sell
1

Hold
9

Buy
14

Based on 24 Wall Street analysts who have issued ratings for Edwards Lifesciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 1 has given a sell rating, 9 have given a hold rating, 11 have given a buy rating, and 3 have given a strong buy rating for EW.

Consensus Price Target

$86.26
11.31% Upside

According to the 24 analysts' twelve-month price targets for Edwards Lifesciences, the average price target is $86.26. The highest price target for EW is $100.00, while the lowest price target for EW is $60.00. The average price target represents a forecasted upside of 11.31% from the current price of $77.50.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for EW and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EW Analyst Ratings Over Time

Type	Current Forecast 9/14/24 to 9/14/25	1 Month Ago 8/15/24 to 8/15/25	3 Months Ago 6/16/24 to 6/16/25	1 Year Ago 9/15/23 to 9/14/24
Strong Buy	3 Strong Buy rating(s)	3 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	11 Buy rating(s)	12 Buy rating(s)	11 Buy rating(s)	11 Buy rating(s)
Hold	9 Hold rating(s)	10 Hold rating(s)	13 Hold rating(s)	14 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$86.26	$85.90	$80.20	$80.29
Forecasted Upside	11.31% Upside	9.77% Upside	7.22% Upside	17.17% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Moderate Buy

EW Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EW Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Edwards Lifesciences Stock vs. The Competition

Type	Edwards Lifesciences	Medical Companies	S&P 500
Consensus Rating Score	2.67	2.78	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	11.31% Upside	17,489.59% Upside	10.72% Upside
News Sentiment Rating	Very Positive News See Recent EW News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/7/2025	Wells Fargo & Company 3 of 5 stars	Larry Biegelsen 1 of 5 stars	Boost Target	Overweight	$84.00 ➝ $88.00	+13.49%
7/29/2025	Daiwa America 5 of 5 stars		Upgrade	Hold ➝ Strong-Buy
7/29/2025	BTIG Research 2 of 5 stars		Upgrade	Neutral ➝ Buy	$100.00	+27.45%
7/25/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
7/25/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
7/25/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$80.00 ➝ $85.00	+6.36%
7/25/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Plovanic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$75.00 ➝ $81.00	+2.36%
7/25/2025	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$87.00 ➝ $95.00	+20.64%
7/25/2025	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$81.00 ➝ $82.00	+2.31%
7/25/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Adam Maeder Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$83.00 ➝ $90.00	+13.33%
Get the Latest News and Ratings for EW and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.
7/25/2025	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$90.00 ➝ $95.00	+19.63%
7/25/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$90.00 ➝ $95.00	+19.63%
7/25/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$85.00 ➝ $89.00	+13.55%
7/25/2025	Evercore ISI Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vijay Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	In-Line	$77.00 ➝ $80.00	+0.28%
7/25/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Pito Chickering Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$85.00 ➝ $94.00	+24.21%
7/25/2025	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Rescott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$78.00 ➝ $79.00	+4.39%
7/15/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$75.00 ➝ $81.00	+3.39%
7/10/2025	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	C. Dooley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
6/2/2025	Dbs Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	N. Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold
5/22/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$84.00 ➝ $95.00	+26.60%
2/12/2025	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
12/16/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$82.00 ➝ $90.00	+20.97%
10/28/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	L. Hambright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/18/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold	$85.00 ➝ $70.00	+4.14%
9/12/2024	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$90.00 ➝ $90.00	+34.71%
9/10/2024	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Neutral	$90.00 ➝ $75.00	+12.66%
7/31/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Neutral ➝ Outperform
7/25/2024	Baird R W Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	D. Rescott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/25/2024	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	J. Jennings Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$100.00 ➝ $70.00	+14.27%
3/26/2024	OTR Global Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Mixed ➝ Positive
10/16/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	M. Kratky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Perform
10/16/2023	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Market Perform	$75.00	+4.90%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:52 AM ET.

Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, September 11, 2025. Please send any questions or comments about these Edwards Lifesciences pros and cons to contact@marketbeat.com.

Edwards Lifesciences
Bull Case

Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.:

Recent upgrades from multiple analysts, including a boost to a "strong-buy" rating, indicate strong confidence in the company's future performance.
The current stock price is around $78.62, which may present a buying opportunity for investors looking for growth in the healthcare sector.
Analysts have set a consensus price target of approximately $85.90, suggesting potential upside from the current price.
Edwards Lifesciences Co. has a solid market capitalization of around $46.16 billion, indicating a stable and established presence in the market.
The company has received multiple "buy" ratings from analysts, reflecting positive sentiment and expectations for continued growth in its product offerings.

Edwards Lifesciences
Bear Case

Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons:

Insider selling activity has been noted, with significant shares sold recently, which may raise concerns about the company's future prospects.
The stock has experienced fluctuations, with a recent trading down of about 1.5%, indicating potential volatility in the short term.
Despite positive ratings, there is still one "sell" rating among analysts, suggesting that not all market participants are confident in the stock's performance.
The company has a relatively high P/E ratio, which could indicate that the stock is overvalued compared to its earnings.
Market conditions can be unpredictable, and healthcare stocks can be particularly sensitive to regulatory changes and market sentiment.

EW Forecast - Frequently Asked Questions

: According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Edwards Lifesciences is $86.26, with a high forecast of $100.00 and a low forecast of $60.00.
: 24 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There is currently 1 sell rating, 9 hold ratings, 11 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EW shares.
: According to analysts, Edwards Lifesciences's stock has a predicted upside of 11.31% based on their 12-month stock forecasts.
: Over the previous 90 days, Edwards Lifesciences's stock had 4 upgrades by analysts.
: Edwards Lifesciences has been rated by research analysts at Argus, Barclays, BTIG Research, Canaccord Genuity Group, Daiwa America, Deutsche Bank Aktiengesellschaft, Evercore ISI, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Piper Sandler, Robert W. Baird, Royal Bank Of Canada, Stifel Nicolaus, The Goldman Sachs Group, Truist Financial, Wells Fargo & Company, and William Blair in the past 90 days.
: Analysts like Edwards Lifesciences less than other "medical" companies. The consensus rating score for Edwards Lifesciences is 2.67 while the average consensus rating score for "medical" companies is 2.78. Learn more on how EW compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:EW) was last updated on 9/14/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Consensus Price Target

EW Analyst Ratings Over Time

EW Analyst Recommendations By Month

EW Price Targets by Month

Edwards Lifesciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

Edwards Lifesciences
Bull Case

Edwards Lifesciences
Bear Case

EW Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Consensus Price Target

EW Analyst Ratings Over Time

EW Analyst Recommendations By Month

EW Price Targets by Month

Edwards Lifesciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

Edwards Lifesciences Bull Case

Edwards Lifesciences Bear Case

EW Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Edwards Lifesciences
Bull Case

Edwards Lifesciences
Bear Case